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Background
SAVI syndrome is a recently identified condition asso-
ciated to mutations of TMEM173. Up to know only few
cases of this disease have been described.
Aim of the study
To describe the clinical manifestation of an Italian
patient affected by SAVI syndrome.
Results
The girl, first born from healthy, not relatives parents, at
the age of 8 months started to present erythematosus-
infiltrated skin lesions with pustular evolution and finally
hesitating in scars in 15-20 days. From the age of three
years chilblains and severe nail dystrophy appeared.
A CT scan performed at the age of 8 years revealed
the presence of diffuse interstitial thickening with
ground-glass appearance. A restrictive framework was
detected at spirometry (FVC 51%).
The autoantibodies detection revealed positive ANA
(1: 160), ANCA (1:80) and Coombs test.
The skin biopsy revealed a predominantly granuloma-
tous nodular dermatitis, with folliculitis and secondary
fibrosis.
The lung biopsy revealed focal hemorrhage, edema and
predominantly lymphocytic inflammatory aggregates in
the peribronchial interstitial areas with aspects of capil-
laritis and contiguous focal subatelettasia with alveolar
cavity filled of macrophages.
Steroidal treatment (prednisone 1 mg/kg/day) was
started with improvement of clinical manifestation, anemia
and normalization of inflammatory markers. However
attempts to reduce such therapy were followed by an
exacerbation of the clinical picture.
Treatment with both immunosuppressive (azathioprine)
and biologic (etanercept) drugs was tempted, without clear
improvement. Unsatisfactory growth was also detected.
In the following months the child started to present a
mild renal involvement with microscopic hematuria and
hypertension, requiring anti-hypertensive treatment.
Given the evocative framework, interferon gene signa-
ture was performed, revealing a significant activation;
the molecular analysis of TMEM173 gene showed the
presence of the de novo Val155Met mutation, already
described as causative of SAVI syndrome.
The child continued to present persistent severe microcy-
tic anemia, requiring erythrocytes’ transfusions, despite high
levels of erythropoietin. Bone marrow aspiration revealed
dysmaturative signs in the in erythroid progenitors.
Treatment with jak1/2 inhibitor (Ruxolitinib, 5 mg day)
was just started at the time of abstract presentation.
Conclusion
This report of the first Italian patient with SAVI syn-
drome confirms the presence of the previously described
clinical manifestations. Persistent hematuria and hyper-
tension are reasonably signs of an underlying renal
involvement, not previously described in this condition.
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